Get started
Author

Claire Xu

Observed name: Claire (Cong) Xu
ORCID: 0009-0007-4646-5435
Observed ORCID: 0009-0007-4646-5435
OpenAlex ID: A5047407147
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
2016 · Yujun Hao, Yardena Samuels, et al. · Nature Communications · 303
PDF
Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results
2021 · Amitkumar Mehta, Wael Harb, et al. · Blood · 34
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al. · Clinical Cancer Research · 25
PDF
Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.
2021 · Francisco Robert, Ecaterina Elena Dumbrava, et al. · Journal of Clinical Oncology · 16
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
2023 · Jaynier Moya, Marisol Temech, et al. · Open Forum Infectious Diseases · 7
PDF
Supplementary Figure 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al. · 1
Urban Heat Island in Wuhan and Its Relationship With Nearby Water Bodies
2020 · Claire Xu · E3S Web of Conferences · 1
PDF
Supplementary Table 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 8 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 1 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Data from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 1 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
845 ABL503 (TJ-L14B), PD-L1×4–1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+T cells and synergizes with PD-1 blockade
2023 · Gihoon You, Seung Hyuck Jeon, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 23
Citation count: 387
H-index: 5
I10-index: 4
Year
Topic
Type